| Title : [New spectrum of HIV-associated cognitive disorders in the HAART era] - Du_2009_Rev.Med.Suisse_5_955 |
| Author(s) : Du Pasquier R , Cavassini M , Simioni S , Annoni JM , Giacobini E , Hirschel B |
| Ref : Rev Med Suisse , 5 :955 , 2009 |
|
Abstract :
Highly active anti-retroviral therapy (HAART) has almost abolished HIV-related mortality and serious opportunistic diseases; among them, AIDS-related dementia. However, minor forms of cognitive dysfunction, have not disappeared, and even increased in frequency. Ageing of HIV+ patients, insufficient penetration of anti-viral drugs into the brain with continuous low-grade viral production and inflammation may play a role. Minor cognitive dysfunction in HIV infection shares some clinical and pathophysiological features with neuro-degenerative diseases, in particular Alzheimers disease. It can thus be postulated that, such in Alzheimer disease, anti-cholinesterase drugs might also be efficacious in AIDS-related minor cognitive dysfunction. This hypothesis has not been tested yet however A clinical trial using ravistigmine is starting this spring in patients with HIV-associated cognitive dysfunction in Geneva and Lausanne. |
| PubMedSearch : Du_2009_Rev.Med.Suisse_5_955 |
| PubMedID: 19476058 |
Du Pasquier R, Cavassini M, Simioni S, Annoni JM, Giacobini E, Hirschel B (2009)
[New spectrum of HIV-associated cognitive disorders in the HAART era]
Rev Med Suisse
5 :955
Du Pasquier R, Cavassini M, Simioni S, Annoni JM, Giacobini E, Hirschel B (2009)
Rev Med Suisse
5 :955